Begin main content

insulin degludec + liraglutide

Last Updated: March 6, 2019
Result type: Reports
Project Number: SR0599-000
Product Line: Common Drug Review

Generic Name: insulin degludec + liraglutide

Brand Name: Xultophy

Manufacturer: Novo Nordisk Canada Inc.

Indications: Diabetes mellitus, Type 2

Manufacturer Requested Reimbursement Criteria1: To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control.

Submission Type: New Combination

Project Status: Active

Biosimilar: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJanuary 02, 2019
Patient group input closedFebruary 21, 2019
Clarification:

- Patient input submission received from Diabetes Canada and Type 2 Diabetes Experience Exchange

Patient input summary sent for review to patient input groupsFebruary 27, 2019
Patient group comments on input summary closedMarch 06, 2019
Clarification:

- Patient input summary feedback received

Submission receivedJanuary 30, 2019
Submission accepted for reviewFebruary 13, 2019
Review initiatedFebruary 14, 2019
Draft CDR review report(s) sent to applicantMay 01, 2019
Comments from applicant on draft CDR review report(s) receivedMay 10, 2019
Redaction requests from applicant on draft CDR review report(s) receivedMay 17, 2019
CDR review team's comments on draft CDR review report(s) sent to applicantJune 07, 2019
Canadian Drug Expert Committee (CDEC) meetingJune 19, 2019
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJuly 02, 2019
To
July 04, 2019

Tags

diabetes